Syros Pharmaceuticals, Inc.

Equities

SYRS

US87184Q2066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.04 ^USD	-1.18%		+11.01%	-35.30%

Apr. 09	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 09	Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	MT

Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 14, 2023 at 06:48 am EST

Syros Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 3.76 million compared to USD 3.89 million a year ago. Net loss was USD 40.14 million compared to USD 30.25 million a year ago. Basic loss per share from continuing operations was USD 1.43 compared to USD 3.21 a year ago. Diluted loss per share from continuing operations was USD 1.43 compared to USD 3.21 a year ago.
For the nine months, sales was USD 9.55 million compared to USD 15.63 million a year ago. Net loss was USD 100.19 million compared to USD 89.88 million a year ago. Basic loss per share from continuing operations was USD 3.59 compared to USD 11.93 a year ago. Diluted loss per share from continuing operations was USD 3.59 compared to USD 11.93 a year ago.

Latest news about Syros Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	Apr. 09	MT
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	Apr. 09	MT
Syros Gets FDA Fast-Track Designation for Tamibarotene	Apr. 09	DJ
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	Apr. 09	CI
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	Mar. 28	DJ
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	Mar. 27	DJ
Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024	Mar. 27
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	Mar. 27	MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27	CI
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	Mar. 25	MT
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	Mar. 25	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Dec. 06	MT
Sector Update: Health Care	Dec. 06	MT
Top Midday Gainers	Dec. 06	MT
Transcript : Syros Pharmaceuticals, Inc. - Special Call	Dec. 06
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine	Dec. 06	CI
Top Premarket Decliners	Nov. 27	MT
Transcript : Syros Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q3 Revenue $3.8M, vs. Street Est of $3.9M	Nov. 14	MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Top Premarket Gainers	23-10-17	MT
Sector Update: Health Care Stocks Lower Late Afternoon	23-10-02	MT
Sector Update: Health Care Stocks Retreating Monday Afternoon	23-10-02	MT

Chart Syros Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARÎ±), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Syros Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.04 USD

Average target price

19.25 USD

Spread / Average Target

+281.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYROS PHARMACEUTICALS, INC.	-35.30%	135M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research